Browse the tables to learn more about the drugs being developed for multiple sclerosis.
Drugs in development
Relapsing remitting MS
| Drug in development | Status |
|---|---|
| ATX-MS-1467 | Phase II |
| Evobrutinib | Phase III |
| Fenebrutinib | Phase III |
| Ixazomib | Phase I |
| Orelabrutinib | Phase II |
| Remibrutinib | Phase III |
| Ublituximab | Phase III |
| Vidofludimus calcium | Phase III |
Secondary progressive MS
| Drug in development | Status |
|---|---|
| Cladribine (Mavenclad) | Phase II |
| Ibudilast | Phase II |
| Ixazomib | Phase I |
| Masitinib | Phase III |
| Tolebrutinib | Phase III |
| Vidofludimus calcium | Phase II |
Primary progressive MS
Myelin repair or neuroprotection
|
Drug in development |
Status |
|---|---|
| Clemastine | Phase II |
| Ibudilast | Phase II |
| Lipoic acid | Phase II |
| Metformin | Phase II |
| Temelimab | Phase II |
What does the drug development process involve?
The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments with many being rejected because of safety, effectiveness or manufacturing problems. On average it will take 10-15 years for a new compound to get from the test-tube into the medicine cabinet.
Not all the treatments listed in these tables will receive a license or be approved for use in the NHS.
Phase I:
The first step in testing a new drug is to determine the safety of single doses in a small number of healthy volunteers.
Phase II:
If the treatment proves to be safe, studies begin to determine the effectiveness of the drug in people with the condition to be treated.
Phase III:
If a drug shows effectiveness, a larger study is conducted in hundreds of people.
Licensing:
Data from all of these three phases is presented to the regulatory authorities.
NHS appraisal:
Once a new medicine has been licensed, drugs may need to be appraised by NICE for England and Wales and SMC for Scotland.
